<DOC>
	<DOCNO>NCT02974660</DOCNO>
	<brief_summary>Transcatheter aortic valve implantation ( TAVI ) new , rapidly emerge standard care inoperable high-risk patient severe , symptomatic aortic stenosis . Information regard reversal unfractionated heparin protamine sulfate order facilitate access site closure scarce base expert consensus . Clinical practice varies center . Protamine sulphate may decrease amount bleed complication relate access-site . The impact possible thromboembolic complication unknown . Both bleed thromboembolic complication increase mortality TAVI . A randomized trial require order assess impact protamine sulfate prevalence extent bleed thromboembolic complication .</brief_summary>
	<brief_title>Protamine Sulfate During Transcatheter Aortic Valve Implantation</brief_title>
	<detailed_description>Information regard reversal unfractionated heparin ( UFH ) protamine sulfate ( PS ) base expert consensus 2012 , recommend use UFH order achieve activate clotting time ( ACT ) &gt; 300 second well UFH reversal PS case TAVI via transapical access well transfemoral access exception case minimal bleeding risk . However , clinical practice varies center - use PS routinely , others - select case . The actual impact PS bleeding complication reduction unknown . Furthermore , pro-thromboembolic effect PS exclude . Both bleed ( major life-threatening accord Valve Academic Research Consortium [ VARC ] criterion ) thromboembolic complication increase mortality TAVI . The occurrence complication international TAVI registries 30-day observation range 9.7 % case major bleeding , 4.7 % case life-threatening bleeds 5 % case stroke . There randomized study assess impact PS frequency bleed thromboembolic complication TAVI , side-effects influence mortality . Randomized trial require order assess impact protamine sulfate prevalence bleed thromboembolic complication .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Protamines</mesh_term>
	<criteria>patient underwent successful TAVI approve TAVI device via transfemoral access use approve vascular closure device provide write informed consent consent periprocedural complication require continuation heparin administration protamine sulfate alergy fish , protamine , protamine derivates , history Humulin N , Novolin N , Novolin NPH , Gensulin N , SciLin N , NPH Iletin II isophane insulin intake</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>